Human LIF Antibody (9824)

R&D Systems | Catalog # MAB250

R&D Systems

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human, Yeast

Applications

Validated:

Immunohistochemistry, Neutralization

Cited:

Immunohistochemistry-Frozen, Western Blot, Neutralization, ELISA Capture, ELISA Development

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 9824
View all LIF Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human LIF

Specificity

Detects human LIF in ELISAs and Western blots. In sandwich immunoassays, no significant cross-reactivity or interference with recombinant human (rh) IL-1 alpha, rhIL-1 beta, rhIL-2, rhIL-3, rhIL-4, rhIL-6, rhIL-7, rhIL-8, rhG-CSF, rhGM-CSF, rhOSM, rhTGF-beta 1, rhTNF-alpha, rhTNF-beta, recombinant mouse (rm) IL-1 beta, rmIL-3, rmIL-4, rmIL-5, rmIL-6, rmIL-7, rmGM-CSF, bovine (b) FGF acidic, bFGF basic, human (h) PDGF, porcine (p) PDGF, hTGF-beta 1, pTGF-beta 1.2, or pTGF-beta 2 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human LIF Antibody (9824)

Cell Proliferation Induced by LIF and Neutralization by Human LIF Antibody.

Cell Proliferation Induced by LIF and Neutralization by Human LIF Antibody.

Recombinant Human LIF stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by 1.5 ng/mL Recombinant Human LIF is neutralized (green line) by increasing concentrations of Mouse Anti-Human LIF Monoclonal Antibody (Catalog # MAB250). The ND50 is typically 0.06-0.2 µg/mL.
Detection of Human LIF by Western Blot

Detection of Human LIF by Western Blot

Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha -SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human LIF by Western Blot

Detection of Human LIF by Western Blot

Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha -SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human LIF Antibody (9824)

Application
Recommended Usage

Immunohistochemistry

8-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human lung

Neutralization

Measured by its ability to neutralize LIF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.06-0.2 µg/mL in the presence of 1.5 ng/mL Recombinant Human LIF. Human LIF Affinity-purified Polyclonal Antibody (Catalog # AF-250-NA) is recommended for neutralization.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: LIF

LIF is a 36‑67 kDa highly glycosylated polypeptide (1, 2) produced by a variety of cells including T cells (3), monocytes (4), fibroblasts (5), osteoblasts (6) and mast cells (7). Consistent with its many synonyms, LIF exhibits a broad spectrum of effects on both hematopoietic and nonhematopoietic cells. For example, LIF inhibits the differentiation of embryonic stem cells (8), up regulates the synthesis of acute phase proteins in hepatocytes (9), down regulates lipoprotein lipase activity in adipocytes (10), and preferentially induces a cholinergic phenotype in sympathetic neurons (11). The receptor for LIF (LIF R) has been isolated and found to be a 190 kDa type I transmembrane glycoprotein (12). Although this molecule binds LIF, the resultant LIF-LIF R complex is not sufficient to transduce an intracellular signal. This capability is provided by a 130 kDa signal transducing subunit (gp130) that is common to the functional receptors for IL-6, IL-11, CNTF, and Oncostatin M (13, 14). Since gp130 is a ubiquitously expressed membrane protein, the presence of LIF R (membrane-bound or soluble form) ultimately determines the cell’s responsiveness to LIF. Cells known to express LIF R include osteoblasts (6), hepatocytes (15), macrophages (15), neurons (5), and megakaryocytes (16). Human and mouse LIF exhibit 78% sequence homology, and human LIF is biologically active on mouse cells (17).

References

  1. Van-Vlasselaev, P. et al. (1992) Prog. Growth Factor Res. 4:337.
  2. Gough, N.M. (1992) Growth Factors 7:175.
  3. Anegon, N.M, I. et al. (1991) J. Immunol.147:3973.
  4. Gillett, N.A. et al. (1993) Growth Factors 9:301.
  5. Banner, L. R. and P.H. Patterson (1994) Proc. Natl. Acad. Sci. 91:7109.
  6. Allen, E.H. et al. (1990) J. Cell. Physiol. 145:110.
  7. Lorenzo, J.A. et al. (1994) Clin.Immunol. Immunopathol. 70:260.
  8. Williams, R.L. et al. (1988) Nature 336:684.
  9. Baumann, H. et al. (1989) J. Immunol. 143:1163.
  10. Marshall, M.K. et al. (1994) Endocrinology 135:1412.
  11. Ludham, W.H. et al. (1994) Dev. Biol. 164:5283.
  12. Davis, S. et al. (1993) Science 260:18054.
  13. Gearing, D.P. et al. (1991) EMBO J. 10:28395.
  14. Gearing, D.P. et al. (1991) Science 255:1434.
  15. Hilton, D.J. and N.A. Nicola (1992) J. Biol. Chem. 267:102286.
  16. Hilton, D.J. et al. (1992) Ciba17. Foundation Symposium 167:2278.

Long Name

Leukemia Inhibitory Factor

Alternate Names

D Factor, Emfilermin, HILDA, MLPLI

Entrez Gene IDs

3976 (Human); 16878 (Mouse); 403449 (Canine)

Gene Symbol

LIF

Additional LIF Products

Product Documents for Human LIF Antibody (9824)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human LIF Antibody (9824)

For research use only

Citations for Human LIF Antibody (9824)

Customer Reviews for Human LIF Antibody (9824)

There are currently no reviews for this product. Be the first to review Human LIF Antibody (9824) and earn rewards!

Have you used Human LIF Antibody (9824)?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies